COVID-19 Treatment-Current Status, Advances, and Gap.

Chian Ho, Ping-Chin Lee
Author Information
  1. Chian Ho: Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia.
  2. Ping-Chin Lee: Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Kota Kinabalu 88400, Sabah, Malaysia. ORCID

Abstract

COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and economic disruption. While clinical trials on therapeutic drugs are going on in an Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership collaboration, current therapeutic approaches and options to counter COVID-19 remain few. Therapeutic drugs include the FDA-approved antiviral drugs, Remdesivir, and an immune modulator, Baricitinib. Hence, therapeutic approaches and alternatives for COVID-19 treatment need to be broadened. This paper discusses efforts in approaches to find treatment for COVID-19, such as inhibiting viral entry and disrupting the virus life cycle, and highlights the gap that needs to be filled in these approaches.

Keywords

References

  1. Am J Ther. 2021 Jun 21;28(4):e434-e460 [PMID: 34145166]
  2. Nat Rev Microbiol. 2021 Mar;19(3):155-170 [PMID: 33116300]
  3. Chem Sci. 2021 Sep 6;12(41):13686-13703 [PMID: 34760153]
  4. N Engl J Med. 2020 Oct 29;383(18):1757-1766 [PMID: 32329974]
  5. Infect Dis Poverty. 2021 May 18;10(1):71 [PMID: 34001244]
  6. ACS Nano. 2020 Apr 28;14(4):5143-5147 [PMID: 32286790]
  7. Science. 2020 Oct 23;370(6515):426-431 [PMID: 32907861]
  8. Nat Struct Mol Biol. 2020 Oct;27(10):925-933 [PMID: 32699321]
  9. J Clin Med. 2021 Apr 07;10(8): [PMID: 33916917]
  10. Lancet Glob Health. 2022 Jan;10(1):e42-e51 [PMID: 34717820]
  11. Clin Infect Dis. 2022 Aug 24;75(1):e491-e498 [PMID: 34467402]
  12. JACC Basic Transl Sci. 2021 Dec;6(12):935-945 [PMID: 34904132]
  13. N Engl J Med. 2021 Feb 25;384(8):693-704 [PMID: 32678530]
  14. Sci Rep. 2021 Jun 1;11(1):11462 [PMID: 34075090]
  15. JAMA. 2020 Dec 8;324(22):2292-2300 [PMID: 33180097]
  16. JAMA Intern Med. 2022 Apr 1;182(4):426-435 [PMID: 35179551]
  17. Biomed Pharmacother. 2021 Nov;143:112107 [PMID: 34488083]
  18. J Vasc Surg Venous Lymphat Disord. 2022 Sep;10(5):1128-1136 [PMID: 35716998]
  19. N Engl J Med. 2022 May 5;386(18):1721-1731 [PMID: 35353979]
  20. Ann Intern Med. 2021 Sep;174(9):1293-1300 [PMID: 34181444]
  21. Sci Rep. 2021 Nov 5;11(1):21768 [PMID: 34741099]
  22. Int J Biol Macromol. 2020 Dec 1;164:2622-2631 [PMID: 32853604]
  23. Cell Res. 2020 Apr;30(4):343-355 [PMID: 32231345]
  24. Commun Biol. 2021 Feb 12;4(1):197 [PMID: 33580154]
  25. Can J Cardiol. 2020 Oct;36(10):1691.e3 [PMID: 32717278]
  26. Cell Rep. 2020 Oct 13;33(2):108254 [PMID: 33007239]
  27. Int J Clin Pharm. 2021 Jun;43(3):764-767 [PMID: 33751323]
  28. Front Pharmacol. 2021 Sep 02;12:698008 [PMID: 34539396]
  29. N Engl J Med. 2021 Jan 21;384(3):229-237 [PMID: 33113295]
  30. Mol Psychiatry. 2022 Apr;27(4):1898-1907 [PMID: 34997196]
  31. J Adv Res. 2020 Mar 16;24:91-98 [PMID: 32257431]
  32. Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149 [PMID: 32747721]
  33. Front Microbiol. 2022 Feb 15;13:813358 [PMID: 35242118]
  34. J Infect Chemother. 2022 Jun;28(6):814-818 [PMID: 35125343]
  35. Int J Mol Sci. 2021 Jan 28;22(3): [PMID: 33525632]
  36. JAMA. 2020 Oct 6;324(13):1307-1316 [PMID: 32876695]
  37. JAMA. 2021 Feb 16;325(7):632-644 [PMID: 33475701]
  38. J Chin Med Assoc. 2020 Mar;83(3):217-220 [PMID: 32134861]
  39. Lancet Respir Med. 2022 Oct;10(10):985-996 [PMID: 35688164]
  40. JAMA. 2020 Jun 23;323(24):2455-2457 [PMID: 32421150]
  41. JAMA Netw Open. 2022 Apr 1;5(4):e226269 [PMID: 35385087]
  42. Curr Pharm Biotechnol. 2022;23(13):1596-1611 [PMID: 35034591]
  43. Int J Environ Res Public Health. 2022 Feb 16;19(4): [PMID: 35206404]
  44. EClinicalMedicine. 2022 Jul;49:101489 [PMID: 35677732]
  45. JAMA. 2021 Nov 9;326(18):1807-1817 [PMID: 34673895]
  46. Science. 2021 Mar 26;371(6536):1379-1382 [PMID: 33597220]
  47. J Inflamm Res. 2020 Oct 29;13:823-828 [PMID: 33149655]
  48. Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66 [PMID: 12360192]
  49. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 03;: [PMID: 35921219]
  50. Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20 [PMID: 34611326]
  51. Nature. 2020 Jun;582(7811):289-293 [PMID: 32272481]
  52. Cochrane Database Syst Rev. 2017 Apr 21;4:CD007557 [PMID: 28431186]
  53. N Engl J Med. 2021 Oct 7;385(15):1382-1392 [PMID: 34260849]
  54. Eur J Clin Invest. 2020 Dec;50(12):e13339 [PMID: 32648935]
  55. J Glob Health. 2021 Apr 24;11:10003 [PMID: 33959261]
  56. Lancet Infect Dis. 2022 May;22(5):622-635 [PMID: 34953520]
  57. Lancet. 2020 Mar 28;395(10229):1033-1034 [PMID: 32192578]
  58. mBio. 2020 Dec 11;11(6): [PMID: 33310780]
  59. J Heart Lung Transplant. 2020 May;39(5):405-407 [PMID: 32362390]
  60. N Engl J Med. 2020 Jun 11;382(24):2327-2336 [PMID: 32275812]
  61. Peptides. 2020 Aug;130:170328 [PMID: 32380200]
  62. N Engl J Med. 2022 Jun 9;386(23):2188-2200 [PMID: 35443106]
  63. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0240421 [PMID: 35862759]
  64. ACS Med Chem Lett. 2020 Oct 25;11(12):2526-2533 [PMID: 33324471]
  65. Int J Biol Sci. 2021 Jul 13;17(11):2957-2969 [PMID: 34345219]
  66. Front Med (Lausanne). 2022 Jul 25;9:951115 [PMID: 35957855]
  67. Life Sci Alliance. 2020 Jul 23;3(9): [PMID: 32703818]
  68. Blood. 2020 Jul 23;136(4):489-500 [PMID: 32492712]
  69. Lancet Glob Health. 2022 Mar;10(3):e331 [PMID: 35180411]
  70. JAMA. 2021 Jul 6;326(1):46-55 [PMID: 34081073]
  71. Cell Rep Med. 2022 Jul 19;3(7):100678 [PMID: 35793677]

Grants

  1. SDK0207-2020/Universiti of Malaysia Sabah

Word Cloud

Created with Highcharts 10.0.0COVID-19drugsapproachescausedtherapeuticTherapeuticFDA-approvedtreatmentviruslifecycleemergedDecember2019declaredglobalpandemicWorldHealthOrganizationWHOMarch2020diseasesevereacuterespiratorysyndromecoronavirus2SARS-CoV-2millionsdeathsworldwidesocialeconomicdisruptionclinicaltrialsgoingAcceleratingInterventionsVaccinesACTIVpublic-privatepartnershipcollaborationcurrentoptionscounterremainincludeantiviralRemdesivirimmunemodulatorBaricitinibHencealternativesneedbroadenedpaperdiscusseseffortsfindinhibitingviralentrydisruptinghighlightsgapneedsfilledTreatment-CurrentStatusAdvancesGapdrugdevelopmentpeptides

Similar Articles

Cited By